IN8bio, Inc. (NASDAQ:INAB) Short Interest Update
IN8bio, Inc. (NASDAQ:INAB) Short Interest Update
IN8bio, Inc. (NASDAQ:INAB – Get Rating) was the target of a significant decline in short interest in August. As of August 31st, there was short interest totalling 33,800 shares, a decline of 17.2% from the August 15th total of 40,800 shares. Based on an average trading volume of 1,300,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.8% of the company's stock are short sold.
IN8Bio，Inc.(納斯達克：INAB-GET評級)是空頭股數8月份大幅下跌的目標。截至8月31日，空頭股數共有33,800股，較8月15日的40,800股下降了17.2%。以130萬股的平均成交量計算，目前的天數與回補比率為0.0天。目前，該公司0.8%的股票被賣空。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, HC Wainwright assumed coverage on IN8bio in a research report on Tuesday, August 30th. They issued a "buy" rating and a $14.00 price target for the company.
另外，HC Wainwright在8月30日星期二的一份研究報告中承擔了對IN8Bio的報道。他們對該公司的評級為“買入”，目標價為14.00美元。
Insiders Place Their Bets
內部人士下注
In other IN8bio news, CEO William Tai-Wei Ho purchased 26,315 shares of the stock in a transaction dated Tuesday, August 16th. The shares were purchased at an average cost of $1.90 per share, with a total value of $49,998.50. Following the completion of the acquisition, the chief executive officer now directly owns 2,315,745 shares in the company, valued at approximately $4,399,915.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO William Tai-Wei Ho acquired 26,315 shares of IN8bio stock in a transaction that occurred on Tuesday, August 16th. The stock was bought at an average price of $1.90 per share, for a total transaction of $49,998.50. Following the completion of the transaction, the chief executive officer now owns 2,315,745 shares in the company, valued at $4,399,915.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Emily Fairbairn acquired 789,473 shares of IN8bio stock in a transaction that occurred on Tuesday, August 16th. The shares were purchased at an average price of $1.90 per share, with a total value of $1,499,998.70. Following the transaction, the director now owns 4,111,958 shares of the company's stock, valued at approximately $7,812,720.20. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 824,208 shares of company stock valued at $1,565,995. 35.80% of the stock is currently owned by corporate insiders.
在另一則IN8Bio新聞中，首席執行官何大偉在8月16日星期二的交易中購買了26,315股該公司股票。這些股票是以每股1.9美元的平均成本購買的，總價值為49,998.50美元。收購完成後，首席執行官現在直接擁有公司2,315,745股，價值約4,399,915.50美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可以在美國證券交易委員會網站上看到。其他消息方面，首席執行官何大偉在8月16日(星期二)的一筆交易中收購了IN8Bio26,315股股票。這隻股票是以每股1.90美元的平均價格購買的，總交易額為49,998.50美元。交易完成後，行政總裁現擁有該公司2,315,745股股份，價值4,399,915.50元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，可以通過美國證券交易委員會網站訪問該文件。此外，在8月16日(星期二)的一筆交易中，董事艾米麗·費爾貝恩收購了IN8Bio789,473股股票。這些股票是以每股1.9美元的平均價格購買的，總價值為1,499,998.70美元。交易完成後，董事現在擁有該公司4,111,958股股票，價值約7,812,720.20美元。此次收購的披露信息可在此處找到。在過去的三個月裏，內部人士購買了824,208股公司股票，價值1,565,995美元。35.80%的股份目前由企業內部人士持有。
Hedge Funds Weigh In On IN8bio
對衝基金對IN8Bio的看法
IN8bio Stock Down 2.4 %
IN8Bio股價下跌2.4%
INAB traded down $0.06 during midday trading on Monday, reaching $2.45. The company had a trading volume of 78,388 shares, compared to its average volume of 506,486. The business has a 50-day moving average of $2.26 and a two-hundred day moving average of $2.68. The company has a market cap of $46.15 million, a P/E ratio of -2.15 and a beta of 0.31. IN8bio has a 1 year low of $1.75 and a 1 year high of $9.42.
Inab在週一午盤交易中下跌0.06美元，至2.45美元。該公司的成交量為78,388股，而其平均成交量為506,486股。該業務的50日移動均線切入位在2.26美元，200日移動均線切入位在2.68美元。該公司市值為4615萬美元，市盈率為-2.15，貝塔係數為0.31。IN8Bio的一年低點為1.75美元，一年高位為9.42美元。
IN8bio (NASDAQ:INAB – Get Rating) last issued its quarterly earnings results on Friday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.05). On average, equities research analysts predict that IN8bio will post -1.29 EPS for the current year.
IN8Bio(納斯達克代碼：INAB-GET Rating)上一次發佈季度收益報告是在8月12日(星期五)。該公司公佈了該季度每股收益(0.38美元)，低於分析師普遍預期的(0.33美元)和(0.05美元)。平均而言，股票研究分析師預測，IN8Bio今年的每股收益將達到1.29歐元。
IN8bio Company Profile
IN8BIO公司簡介
(Get Rating)
(獲取評級)
IN8bio, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation.
IN8Bio，Inc.是一家臨牀階段的生物技術公司，專注於治療癌症的伽馬-德爾塔T細胞療法的發現、開發和商業化。它的主要候選產品包括INB-200，這是一種用於治療膠質母細胞瘤和實體瘤的轉基因自體伽馬-德爾塔T細胞候選產品，目前處於第一階段臨牀試驗；以及INB-100，一種異基因產品候選產品，正在進行第一階段臨牀試驗，用於治療接受造血幹細胞移植的急性白血病患者。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on IN8bio (INAB)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- 免費獲取StockNews.com關於IN8Bio的研究報告(INAB)
- 仍然愛着它：投資者繼續光顧麥當勞
- 聯邦快遞剛剛提供了一個買入機會嗎？
- 自動區重新進入拉力賽模式，新高在望
- Upwork股價跌入便宜貨領域
- 克羅格百貨是你的一站式消費者史泰博股票
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
接受IN8Bio日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對IN8Bio和相關公司的最新新聞和分析師評級的每日簡明摘要。